Here's what to know about the deadly flooding, the colossal weather system that drove it in and around Kerr County, Texas, ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

INmune Bio’s XPro shows promise for Alzheimer's with neuroinflammation despite Phase II miss. Read here for a detailed ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with ...